Overview
ONO PHARMA USA, INC. (OPUS) was established in 1998 as the US subsidiary of Ono Pharmaceutical Co., Ltd. (ONO), an R&D-oriented pharmaceutical company with headquarters in Osaka, Japan. ONO was founded in 1717 and has made progress for more than 300 years in our commitment to relieve patient’s pain and focus on improving their health. ONO has succeeded in delivering “First in class” medicines to patients including OPDIVO® (nivolumab). OPUS is pursuing clinical trials of our new drug candidates and continuously and vigorously promotes licensing activities as a potential means of expanding our development pipeline and globally marketing the new drugs we develop.